Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying the window of aggressive postpartum breast cancer based on the 21-gene Oncotype DX® test in women with HR+, HER2-negative breast cancer.

NPJ breast cancer·2026
Same author

Histological study to assess CO<sub>2</sub> laser therapy for the treatment of vaginal atrophy.

European journal of obstetrics, gynecology, and reproductive biology·2026
Same author

A Maturity Model for REDCap-Based Patient-Facing Technologies: A Roadmap Toward Patient-Centered Intelligence.

Studies in health technology and informatics·2026
Same author

An Automated Synchronization Strategy for MAUDE Literature Dashboard.

Studies in health technology and informatics·2026
Same author

Complicated intra-abdominal fibromatosis masked by a perforated jejunal diverticulitis.

BMJ case reports·2026
Same author

The 5-item Modified Frailty Index is a Predictor of Pulmonary Complications in Total Knee Arthroplasty.

Orthopedic reviews·2026
Same journal

Discovery of a potent sGC stimulator with once-daily dosing potential for the treatment of hypertension.

Bioorganic & medicinal chemistry letters·2026
Same journal

OracleScreen-LILRB4 (HTS-Oracle v3): machine learning-guided discovery of myeloid immune checkpoint binders validated in patient-derived cells.

Bioorganic & medicinal chemistry letters·2026
Same journal

Rational design and N-terminal acylation of a lactam-cyclized 11-residue antimicrobial peptide for improved antibacterial potency.

Bioorganic & medicinal chemistry letters·2026
Same journal

Rational design, synthesis, and biological evaluation of chalcone hybrids including benzoylpiperazin (phenylacetylpiperazin)-thiophene as anti- Alzheimer's agents.

Bioorganic & medicinal chemistry letters·2026
Same journal

New aminopiperidine-azoles as antifungal agents against Candida albicans with mechanistic insights into the cAMP-PKA pathway.

Bioorganic & medicinal chemistry letters·2026
Same journal

Novel 1H-pyrrole-2,5-dione derivatives as potential anti-diabetic agents: design, synthesis, in vitro, in ovo, and molecular docking studies.

Bioorganic & medicinal chemistry letters·2026
See all related articles

Related Experiment Video

Updated: May 31, 2026

Quantitative Measurement of &#947;-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
06:40

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

Pyridine-derived γ-secretase modulators.

Zehong Wan1, Adrian Hall, Yingxia Sang

  • 1Research and Development, GlaxoSmithKline Pharmaceuticals, 898 Halei Road, Zhangjiang Hi-tech Park, Pudong, Shanghai 201023, China. Zehong.2.Wan@gsk.com

Bioorganic & Medicinal Chemistry Letters
|July 12, 2011
PubMed
Summary
This summary is machine-generated.

Researchers developed novel pyridine-derived gamma-secretase modulators. Compound 5 effectively reduced amyloid-beta 42 (Aβ42) and Aβ40 levels in vitro and in vivo without impacting Notch signaling.

More Related Videos

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by &#947;-Secretase
11:57

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Published on: June 24, 2025

Related Experiment Videos

Last Updated: May 31, 2026

Quantitative Measurement of &#947;-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
06:40

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by &#947;-Secretase
11:57

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Published on: June 24, 2025

Area of Science:

  • Medicinal Chemistry
  • Neuroscience
  • Pharmacology

Background:

  • Alzheimer's disease is characterized by the accumulation of amyloid-beta (Aβ) peptides.
  • Gamma-secretase modulators offer a therapeutic strategy by altering Aβ production.
  • Developing selective modulators that reduce toxic Aβ species is crucial.

Purpose of the Study:

  • To describe the structure-activity relationship (SAR) of novel pyridine-derived gamma-secretase modulators.
  • To identify potent compounds for reducing pathogenic Aβ species, particularly Aβ42.
  • To evaluate the in vitro and in vivo efficacy and safety profile of lead compounds.

Main Methods:

  • Synthesis and SAR analysis of a novel series of pyridine-derived compounds.
  • In vitro biochemical assays to assess gamma-secretase modulation and Aβ peptide levels (Aβ42, Aβ40, total Aβ).
  • In vivo studies in animal models to evaluate brain Aβ42 levels and peripheral Notch processing.

Main Results:

  • Compound 5 emerged as a potent gamma-secretase modulator in vitro.
  • Compound 5 demonstrated a significant decrease in Aβ42 and Aβ40 levels, while maintaining or increasing total Aβ.
  • Compounds 1 and 5 showed in vivo efficacy in lowering brain Aβ42 without adverse effects on peripheral Notch processing.

Conclusions:

  • Novel pyridine-derived compounds are effective gamma-secretase modulators.
  • Compound 5 represents a promising therapeutic candidate for reducing Aβ pathology.
  • The developed modulators show a favorable safety profile regarding Notch pathway interference.